Aktuellt
SENASTE
Nexstim announced today that its ongoing pilot study using an accelerated TMS protocol to treat chronic neuropathic pain has been slightly delayed due to the pandemic. The company will continue to recruit patients during Q3 (previously H1). We consider the delay a minor issue, also as we do not value the accelerated treatment protocol at this point, and thus do not make any changes to our valuation of the company.
LÄS MER
